摘要
目的:分析重组人C1酯酶抑制剂(rhC1INH)中相关蛋白rcc-rhC1INH和ox-rhC1INH的含量。方法:采用反相高效液相色谱法进行测定,对该方法进行专属性、准确性和精密度检验,并用该方法对4批样品中的相关蛋白进行检测。结果:低浓度下,rhC1INH对照品、rcc-rhC1INH对照品和ox-rhC1INH对照品能够较好分离。rcc-rhC1INH和ox-rhC1INH 2种对照品质量浓度为0.2、1和1.4 mg·mL^(-1)时的回收率均在85%~115%的范围内。对同1批3个待测样品进行测定,rcc-rhC1INH含量为(0.082±0.008)%,RSD为9.8%;ox-rhC1INH含量为(0.35±0.05)%,RSD为14.3%,显示该方法具有较好的专属性、准确性和精密度。4批测试样品中,rcc-rhC1INH的含量分别为0.083%、0.021%、0.033%、0.042%,ox-rhC1INH的含量分别为0.34%、0、0、0。结论:经方法学验证,RP-HPLC方法可用于rhC1INH中rcc-rhC1INH和ox-rhC1INH的含量检测。
Objective:To analyze the contents of related proteins rcc-C1 INH and ox-C1 INH in the recombinant human C1 esterase inhibitor(rhC1 INH). Methods:The reversed phase high-performance liquid chromatography(RP-HPLC) was used to determine the relative proteins,the test was verified in specificity,accuracy and precision,and was used to detect the rcc-C1 INH and ox-C1 INH in 4 batches of samples. Results:RhC1 INH reference,rcc-rh C1 INH reference and ox-rhC1 INH reference could be well separated under the low concentrations.The recovery rates for the reference substances of rcc-C1 INH and ox-C1 INH at three concentrations(0.2,1 and 1.4 mg·mL-1) were all in the range of 85%~115%. Three groups from one batch were determined separately,the contents of rcc-C1 INH were(0.082±0.008)%,and the contents of ox-C1 INH were(0.35±0.05)%,with RSDs of 9.8% and 14.3%,respectively. This method showed good results in specificity,accuracy and precision. Four batches of rhC1 INH were determined,the contents of rcc-C1 INH were 0.083%,0.021%,0.033% and 0.042% for each,and ox-C1 INH were 0.34%,0,0,and 0,respectively. Conclusion:RP-HPLC can be used for the content determination of rcc-rhC1 INH and ox-rhC1 INH in rhC1 INH.
作者
秦玺
姚文荣
丁有学
史新昌
韩春梅
陶磊
李永红
饶春明
QIN Xi;YAO Wen-rong;DING You-xue;SHI Xin-chang;HAN Chun-mei;TAO Lei;LI Yong-hong;RAO Chun-ming(National Institutes for Food and Drug Control,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,Beijing 100050,China)
出处
《药物分析杂志》
CAS
CSCD
北大核心
2018年第11期1911-1916,共6页
Chinese Journal of Pharmaceutical Analysis
基金
药品医疗器械审评审批制度改革专项课题(ZG2017-3-02)
十三五科技重大专项课题"生物类似药质量相似性评价体系建设研究"(2015ZX09501008)